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Abstract
Background: Despite great advances in clinical oncology, the molecular mechanisms underlying
the failure of chemotherapeutic intervention in treating lymphoproliferative and related disorders
are not well understood.
Hypothesis:  A hypothetical scheme to explain the damage induced by chemotherapy and
associated chronic oxidative stress is proposed on the basis of published literature, experimental
data and anecdotal observations. Brief accounts of multidrug resistance, lymphoid malignancy, the
cellular and molecular basis of autoimmunity and chronic oxidative stress are assembled to form a
basis for the hypothesis and to indicate the likelihood that it is valid in vivo.
Conclusion: The argument set forward in this article suggests a possible mechanism for the
development of autoimmunity. According to this view, the various sorts of damage induced by
chemotherapy have a role in the pattern of drug resistance, which is associated with the initiation
of autoimmunity.
Background: review of the literature
Multi-drug resistance: a multi-step process
After exposure to chemotherapeutic drugs, lymphoid cells
develop along two distinct pathways. First, a cell popula-
tion susceptible to the drugs dies by apoptosis or necrosis,
depending on the severity of treatment. Secondly, a few
cells evolve one or more mechanisms for survival, resist-
ing the damage inflicted by the drugs. It is well known that
chemotherapeutic drugs induce tumor cell death via
apoptosis through DNA damage, and, in particular, acti-
vation of proteolytic enzymes involved in programmed
cell death. When one drug fails, various others are tried as
parts of a therapeutic regimen. Such drugs kill cancer cells
by increasing their sensitivity via alterations in internal
mechanisms, a desired outcome for effective chemother-
apy. Some tumor cells evolve mechanisms, as yet poorly
understood, by which they acquire resistance to structur-
ally and functionally unrelated drugs; this is referred to as
multi-drug resistance.
Multi-drug resistance: a selective adaptation mechanism
Distinct factors contributing to the formation of tumori-
genic phenotypes ensure that each malignant cell is
unique in terms of activation of oncogenes and inactiva-
tion of tumor suppressor genes. Drug-exposed tumor cells
are subjected to sustained to oxidative stress and become
tolerant to it. During this time window, selection pressure
imposed by the chemotherapeutic drugs causes the selec-
tive overgrowth of cells that can withstand them. It is also
possible that normal, but susceptible, cells may acquire
drug resistance by cellular overgrowth in their neighbor-
hood [1].
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Multi-drug resistance: an intrinsic or acquired 
phenomenon
Development of drug resistance could be either intrinsic
or acquired during neoplasia formation. Intrinsic resist-
ance is possibly an inherent property of the species, devel-
oped during the course of evolution. Acquired drug
resistance possibly originates in the host because of one or
more of the following factors: 1. reduced absorption of
the specific drug; 2. delayed/expedited rate of metabolism
by the specific organ involved; 3. loss of drug accumula-
tion mechanism (decreased import); 4.  increased drug
elimination (increased export) (e.g. multi-drug resistance
in cancer cells); 5. conversion of active drug to an inactive
form (e.g. penicillinase, insecticide resistance) or to a pro-
drug no longer converted to its active form (e.g. resistance
to purine analogues in cancer cells); 6. elimination of tar-
get (e.g. induction of alternative pathway) or alteration of
target's affinity for the drug; 7. overproduction of target
(e.g. gene amplification); 8. accumulation of metabolite
antagonistic to drug (e.g. PABA overproduction by Pneu-
mococci) [2].
Multi-drug resistance: evolution by inhibition of 
apoptosis
These factors contribute towards reducing the level of the
drug in the serum. Other factors contributing to the evo-
lution of drug resistance and inhibition of apoptosis may
include: tolerance to the drug effects; failure and/or lack of
delivery of a given drug to the tumor site (owing to size or
location of the tumor, or low absorption rate of a high
molecular weight drug); and non- specific interactions of
drugs with healthy cells [3,4]. As a result, each malignant
cell is unique in terms of activation of oncogenes and
inactivation of tumor suppressor genes and hence in the
tumorigenic phenotypes to which it can give rise; any
given tumor cell population becomes heterogeneous [5].
Although many studies have demonstrated the critical
role of anti-apoptotic components including Bcl-2, Bcl-xL
and Mcl-1, and proapoptotic components such as Bax,
Bak and Bad, in the evolution of multi-drug resistance, the
underlying molecular mechanism is not clear at present.
Overexpression of Bcl-2, Bcl-xL or Mcl-1 has been shown
to prevent drug-induced apoptosis in several cell lines
[6,7].
Multi-drug resistance: role of epigenetic mechanism(s)
It has been suggested that drug resistance is implicitly
mediated via epigenetic changes in the form of altered
gene expression induced by transacting factors, and is def-
initely not due to alteration of the tumor cell genome.
However, the DNA double strand breaks (dsbs) are con-
sidered responsible for drug toxicity and are linked to cell
death, mostly via apoptosis [8,9]. Drug-sensitive cells
exposed to alkylating agents manifest a sustained increase
in reactive oxygen species (ROS) levels along with DNA
dsbs. ROS and dsbs are suggested causes of drug sensitive
tumor cell death via apoptosis. Furthermore, after a
period of time without exposure to alkylating agents, drug
resistant cells in culture become sensitive and die via
apoptosis. It is tempting to speculate that the drug resist-
ance observed in vitro is a transient or evanescent phe-
nomenon. This may not be the case in the in vivo or
clinical scenario, which would severely limit the ability to
correlate  in vitro findings with clinical manifestations
(Kannan, unpublished data).
Multi-drug resistance: possible role of DNA damage-
dependent mechanisms
In addition, acquired resistance to the alkylating family of
drugs has been attributed to such factors as increased
expression of glutathione-S-transferase (GST) and
changes associated with signaling events upstream of the
site of the action of Bcl-2 family members. It is implied
that genes conferring protection from apoptosis are up-
regulated in the surviving cells and confer drug resistance.
The steps involved in the formation of resistance to
alkylating agents involve the following sequence: cellular
uptake of the drug [10], conversion to the active form, for-
mation of DNA-mono adducts, cross-link formation, and
detoxification of the free intracellular drug or its reactive
metabolite, e.g. by conjugation with reduced glutathione
by GST [4].
Multi-drug resistance: possible role of DNA damage-
independent mechanisms
However, it has also been proposed that drug resistance
can evolve independently of DNA damage and repair
[11]. Oxidative stress-induced DNA damage could be
overcome in drug-sensitive tumor cells, but it probably
occurs through the loss of appropriate antiapoptotic
genes, so the sensitive cells undergo apoptosis. Drug-
resistant cells overcome oxidative stress by efficiently
repairing the as-yet-unknown extent of damage in
genomic DNA, resulting in a drug resistance genotype. In
terms of DNA repair, an alkylating agent-resistant pheno-
type of B-cell chronic lymphocytic leukemia has been
attributed to rapid inter-strand, cross-link repair, and also
to upregulation of double-strand repair proteins with
increased formation of nuclear foci [12].
Owing to the sustained accumulation of DNA strand
breaks and impairment of the DNA double-strand break
repair machinery, such as homologous recombination
(HR) and non-homologous endjoining (NHEJ), along
with genomic instability to the alkylating agents, the
resistant cells undergo apoptosis [13]. In a comparative
study using variants of human ovarian carcinoma cells
sensitive or insensitive to alkylating agents, it was found
that increased levels of anti-apoptotic proteins prevent the
drug-resistant cells dying from apoptosis. In contrast, byTheoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
Page 3 of 16
(page number not for citation purposes)
producing increased levels of pro-apoptotic proteins, the
drug-sensitive cells were rendered apoptotic. The sensitive
cells were shown to undergo more free radical formation
and genomic DNA damage with the impairment of DNA
damage repair mechanisms [[14-16]; Kannan, unpub-
lished observations].
Malignant lymphocyte disorders
Lymphocyte malignancies encompass the development of
lymphocyte neoplasms from cells at a stage before their
differentiation to T- and B- cells; i.e. either primordial or
differentiated stem cells. In particular, acute lymphocytic
leukemias are known to originate from the primitive lym-
phoid stem cells that normally differentiate into T- or B-
cell phenotypes, whereas chronic lymphocytic leukemias
arise from a well- differentiated B-cell progenitor. It is also
known that multiple myelomas are likely to originate
from B cells at a later stage of maturation. Depending on
the various regulatory molecules involved in stem cell
development, the ensuing lymphocytic disease might be
of several kinds: I. hairy-cell leukemia, II. prolymphocytic
leukemia, III. natural killer-cell large granular lymphocytc
leukemia and IV. plasmacytoma.
Both B-cell and T-cell neoplasms constitute a multiplicity
of disorders depending on the developmental stage (see
table 96-1 in[17]). Secretions of monoclonal proteins (a
distinctive class of immunoglobulins) are an essential fea-
ture of both neoplastic transformation and clonal prolif-
eration in B cells. Owing to the increase in secretory
protein levels in the circulation, the viscosity of the blood
is increased and erythrocytes aggregate, causing a hyper-
viscosity syndrome [18]. Moreover, immunoglobulins
that precipitate below 37°C are known to cause Raynaud
syndrome, skin ulcerations, purpura, digital infarction
and gangrene. Deposition of immune complexes in the
glomerular tufts is a critical factor in the evolution of a
spectrum of renal diseases. Formation and accumulation
of excess immunoglobulin heavy chains in plasma cell
myelomas causes amyloids, resulting in primary amy-
loidosis.
The generation of immunoglobulins that recognize self
antigens, referred to as auto-reactive antibodies, during B-
cell neoplasia is known to cause autoimmune thrombocy-
topenia and possibly autoimmune neutropenia. Antibod-
ies directed against tissue proteins are factors in the
etiopathogenesis of autoimmune thyroiditis, adrenalitis,
encephalitis, and, conceivably, peripheral neuropathies.
Although neuropathy is not a common sequela, orga-
nomegaly, endocrinopathy or POEMS syndrome are
potential outcomes (reviewed in [17]). Malignant B-cell
infiltration into bone marrow suppresses hemopoiesis,
causing anemia, granulocytopenia and possibly thrombo-
cytopenia. While combinations of proliferating and infil-
trating malignant B-cells are a significant factor in the
genesis of splenomegaly and lymphadenopathy of super-
ficial or deep lymph nodes, malignant B-cells in prolym-
phocytic or hairy cell leukemia, after infiltrating the bone
marrow and spleen, may cause spleen enlargement
(reviewed in [17]).
Cutaneous T-cell lymphomas are associated with elevated
levels of Th-2-type-associated cytokines such as IL-2, IL-4,
IL-5, IL-10, IL13, IFN-γ, TNF-β, TNF-α and GM-CSF,
which might compound the occurrence of eosinophilia
and eosinophilic pneumonia [19]. The neoplastic plasma
cells in multiple myeloma secrete IL-1, causing the stimu-
lation of osteoclast proliferation, oteolysis, severe bone
pain and pathological fractures [20]. Moreover, in lym-
phoma-associated hemo-phagocytic syndrome, excessive
secretion of IL-1 might play a role in the inappropriate
secretion of antidiuretic hormone [21]. It has been sug-
gested that the uncontrolled extra-renal production of cal-
citriol is the major humoral mediator of hypercalcemia in
both Hodgkin's disease and non-Hodgkin's lymphomas
[22]. Lymphocytic malignancies are known to be sensitive
to cytotoxic drugs, causing hyperuricosuria, hyperkalemia
and hyperphosphatemia. These abnormalities result from
metabolic disruption and are collectively referred to as
"tumor lysis syndrome" [23].
Cutaneous T-cell lymphomas encompass malignant cells
that home to skin, occasionally producing desquamating
erythroderma, as observed in Sézary syndrome, nodular
infiltrative lesions, and, in specific incidences, mycosis
fungoides. Lymphocytic leukemia and lymphoblastic
lymphomas of T-cell origin are associated with the
enlargement of mediastinal regions. B-cell lymphomas
have frequently been observed in bones, bowel, kidneys,
lungs, heart, joints, endocrine and salivary glands and less
frequently in the extra-nodal regions. Marginal zone B-cell
lymphomas of the mucosa-associated lymphoid tissue
(MALT) type have been recorded mostly in the stomach
and also in the salivary glands, though extra-nodal origin
is a possibility, as indicated by columnar or cuboidal epi-
thelium in staging (reviewed in [17]).
Loss of self-tolerance and onset of autoimmunity: a muti-
factorial phenomenon
Among the foremost risk factors for the development of
autoimmune diseases are polymorphisms among genes
regulating the onset of the self-tolerance and immune reg-
ulation – (autoimmune regulator (AIRE), the T cell immu-
noglobulin and mucin-domain-containing (TIM) gene
family, and cytolytic T lymphocyte-associated antigen 4
(CTLA-4)) – which have a significant role in sustaining
self-tolerance and in the onset of autoimmunity (reviewed
in [24-26]). AIRE null mice develop multi-organ failure
because of the specific reduction in ectopic transcriptionTheoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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of genes encoding peripheral antigens. On the basis of
these findings it has been suggested that thymically-
imposed "central" (self) tolerance plays a pivotal role in
the in genesis of autoimmunity [27].
Cellular basis of antigen presentation and cross-
presentation: role of MHC and T-cells
In particular, the MHC haplotype contributes either by
enabling peptide epitopes to be presented in the periph-
ery, increasing T cell activation, or by aborting the presen-
tation of self(host)-antigens in the thymus. As a result,
more aggressive T cells or fewer regulatory T (Treg) cells
are formed in the host. It is known that Th1-type
responses such as interferon-γ [IFN-γ] and interleukin 12
[IL-12] are associated with destructive autoimmune
responses, while Th2-type responses (IL-4, IL-5, IL-13)
counter-regulate cell-mediated autoimmune processes
[28].
Helper T (CD4+) cells recognize peptides presented by
MHC class II molecules, whereas cytotoxic T cells (CTLs/
CD8) recognize peptides presented by MHC class I. MHC
class II molecules present peptides originating from exog-
enous sources that enter the cell by endocytosis. MHC
class I molecules present antigens of endogenous origin,
which are synthesized within the cells. Dendritic cells also
process exogenous antigens into the MHC class I pathway;
this is referred to as "cross-presentation". As a result, host
immune systems generate immunity to exogenous agents
and develop tolerance to self antigens. Therefore, cross-
presentation is a typical source of indiscriminate presenta-
tion of self and foreign antigens [29]. The thymus is the
control center where potentially aggressive T cells specific
for autoantigens are eliminated and CD4+CD25+  Treg
cells that recognize autoantigens are selected. Observa-
tions on T cell antigen receptor (TCR) transgenic mice
show that the thymus regulates the release of antigen-spe-
cific CD4+CD25+ Treg cells into the peripheral circulation
[30].
Regulatory role of pro-inflammatory and regulatory 
cytokines in the onset of autoimmunity
As per the generally-accepted mechanism for the patho-
genesis of autoimmune diseases, naive T cells upon activa-
tion by antigen produce IL-2 and then undergo clonal
expansion and produce pro-inflammatory cytokines
(tumor necrosis factor, TNF). CD4+ T cells differentiate
into at least two subsets of helper cells, T helper 1 (Th1)
and T helper 1 (Th2). Th1 produce IFN-γ and lympho-
toxin-α under regulation by IL-12, which activates the
lymphocyte transcription factor STAT4 (signal transducer
and activator of transcription 4) and plays a significant
role in the onset of autoimmunity. In contrast, Th2 cells
produce IL-4, which constrains cell-mediated immunity
(CMI) and possibly inhibits the onset of autoimmune dis-
ease. Attenuation of the IL-10 and transforming growth
factor-β (TGF-β) effect has been shown to result in inflam-
mation and the onset of autoimmune diseases. In the con-
text of lymphoid malignancy and autoimmunity, the
absence of STAT3 from myeloid cells results in the onset
of autoimmune diseases [31].
Therefore, the balance between proinflammatory (IL-2,
IFN-γ and TNF) and regulatory (IL-4, IL-10 and TGF-β)
cytokines probably determines any predisposition to
develop autoimmune disease. IL-2 is known to mediate
apoptosis through two different pathways, passive cell
death (PCD) [32] and activation-induced cell death
(AICD) [33]. PCD occurs mostly because crucial pro-sur-
vival signals are absent. Lack of cytokine signaling has
been shown to cause an increase in mitochondrial perme-
ability and cytochrome c  release; along with apoptotic
protease-activating factor 1 (APAF1), cytochrome c acti-
vates caspase-9 and downstream effector caspases. AICD,
which is essential for the pathogenesis of autoimmunity
and autoimmune lymphoproliferative syndrome, occurs
mainly because of IL-2 mediated signaling via the death-
domain-containing receptor Fas (CD95).
After the Fas-associated death domain (FADD) is acti-
vated, caspase-8 becomes active and downstream signal-
ing results in cell death. Fas/Fas ligand (FasL; CD178) are
deficient in autoimmune lpr and gld mice, which develop
profound lymphadenopathies. The autoimmune lym-
phoproliferative disease (ALPS) found in humans is also
consequent on mutations in Fas [33,34]. Furthermore, IL-
2 has been shown to upregulate CTLA-4 (cytotoxic T-lym-
phocyte-associated protein 4; CD152), and CTLA-4-defi-
cienciy leads to a fatal lymphoproliferative disease that is
more aggressive than the lymphoproliferative disorders
caused by either IL-2 or Fas deficiency [35]. However,
abrogation or attenuation of chemokine induction
(CXCL10, IP-10, inflammatory cytokines) at an auxiliary
location would be likely to impair the onset of autoim-
mune disorder[36].
Neo-antigens and molecular mimicry
The structures of host macromolecules and small mole-
cules are markedly altered by acute or chronic oxidative
stress and can behave as antigens ("neo-antigens"). Neo-
antigens with sufficient homology or identity to host anti-
genic proteins prompt auto-reactivity. This phenomenon
is referred to as "molecular mimicry". A detailed study
demonstrating molecular mimicry linkages between
viruses and host structures has been reported [37].
Drug metabolism is well known to generate neo-antigens
in the form of protein adducts [38,39]. Potentially,
chronic oxidative stress (COS) could be a slowly-evolving
concomitant of the generation of mimetic neoantigens.Theoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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Over time, COS could generate several adducted and/or
non-adducted molecules that would essentially act as a
"neo-antigens". This is consistent with the slow matura-
tion of auto-antibodies in the evolution of autoimmune
diseases. In practice, it is possible that more than one neo-
antigens/autoantigens are involved in amplifying the
autoaggressive lymphocytes by a process referred to as
"antigen spreading". This is an autoimmune reaction ini-
tially directed against a single autoantigen that spreads to
other autoantigens, causing the T helper cells to recognize
them [40].
Molecular mimicry is most important cause of 
autoimmunity after viral infection
Molecular mimicry results in self-reactive T cells that are
activated by cross-reactive ligands originating from infec-
tious pathogens. It is of pivotal significance that molecu-
lar mimicry alone, in the context of infection, could not
initiate an autoimmune disorder. However, in combina-
tion with various cellular factors (epitope avidity and
extent of CD8+ T cell activation), it may accelerate the
process [41]. By utilizing distinct viral strains, it has been
shown that T-cell receptor (TCR) affinity, and also nega-
tive regulatory molecules of host origin, are likely to play
a crucial role in attenuating autoimmunity. It has further
been suggested that autoimmune diseases per se are due to
combinations of genetic and environmental factors. In
particular, the affinity between the TCR and activating
peptide-MHC ligand is essential; it might act as a limiting
factor in eliciting an autoimmune response by molecular
mimicry [42].
On the basis of these premises, it is argued that the
amounts of genotoxic drugs and their adduct-forming
metabolic derivatives probably play a pivotal role in accel-
erating autoimmune processes. Of course, they would act
in combination with host-derived regulatory factors and
the outcome would depend on the genetic predisposition
of the individual. COS is highly likely to predispose an
individual to an autoimmune disorder simply because the
intrinsic defense mechanisms are depleted.
"Bystander effect" and its role in the breakdown of self-
tolerance: a positive regulator of the onset of 
autoimmunity
During COS, neo-antigens with target organ specificity
potentially cause tissue damage and release a plethora of
sequestered auto-antigens. This process is referred to as
the "bystander effect". Such an outburst of autoantigens
from the target tissue would potentially amplify the effect
of the neo-antigens, leading to the breakdown of self-tol-
erance. To date, there is no definitive evidence that the
host is either primed or programmed to bestow tolerance
on the newly-evolving antigens resulting from COS.
Chemical immunomodulation
Although the drugs used in clinical oncology are of low
molecular weight, they cannot activate T cells but sensitize
specific lymphocytes. Subsequent contact with a similar
chemical or a metabolic derivative induces neo-antigens,
which in combination with sufficient co-stimulatory sig-
nals cause the release of proinflammtory cytokines (e.g.
IL-2, IL-7) and co-stimulatory mediators. This in turn
causes the activation of neutrophils, monocytes, macro-
phages and complement pathways. It is reasonable to
envisage that chemical activation of a leukocyte popula-
tion releases pro-inflammatory cytokines, which in turn
determine whether the host develops sensitivity or toler-
ance. It should be pointed out that drug-induced immune
derangements are similar to those in graft-vs-host diseases
[43].
Immune response(s) to chemical stimulants
Owing to the overwhelming antigenic load in the host,
naive T-cells (Th0) are activated and form Th1 or Th2 sub-
populations. The Th1 response is characterized by the iso-
type specificity of the immunoglobulins formed (IgG2a
and IgG2b), while the TH2 response is characterized by
elevated levels of IgG1 and IgE. In most instances the ini-
tial APC is a dentritic cell (DC, CD80+, CD86+), but B-
lymphocytes are the APCs for some chemicals that stimu-
late Th2 [44,45]. The immune modulation caused by a
chemotherapeutic drug need not resemble the effects of its
metabolic derivatives. It is therefore virtually impossible
to determine the specific cause and effect relationship in a
chemotherapeutic drug-induced autoimmune disease
[46].
Chemically-induced co-stimulatory signals
The following evidence supports the notion that COS
plays a role in autoimmunity. Protein adducts generated
as a result of oxidative metabolism of 2-bromo-2-chloro-
1,1,1,-trifluoroethane (TFA-protein adducts) in CYP450
2E1 induce fulminant autoimmune-mediated halothane
hepatitis [47]. TFA-protein adducts are structurally similar
to the pyruvate dehydrogenase complex (PDC), which
was identified as an autoantigen causing primary biliary
cirrhosis, resulting in progressive destruction of the bile
ducts [48]. Since sub-clinical primary biliary cirrhosis
(PBC) is not easily diagnosed, the pathogenesis of PBC
subsequent to the immune response to TFA-protein
adducts or PDC might be due to acceleration of a pre-
existing sub-clinical PBC. Protein modifications that lead
to the formation of ("non-self") neo-antigens induce
halothane hepatitis. At present there is no direct evidence
to implicate TFA-adducts in co-stimulation per se.Theoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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Role of metabolites/metabolic intermediates in the onset 
of autoimmunity
Aberrant induction of self-tolerance, chromatin-reactive T
cells, auto-antibodies to chromatin, and inhibition of
unresponsiveness to low-affinity auto-antigens (self-com-
ponents) in the thymus during positive selection are char-
acteristic effects of procainamide (procainamide-
hydroxylamine) metabolites [49]. Administration of anti-
CTLA-4 (blocking Ab) in mice that are susceptible to mer-
curic chloride (HgCl2) induced autoimmunity causes an
increase in anti-nucleolar auto-antibodies. In DBA/2
mice, which are resistant to heavy metal-induced autoim-
munity, similar treatment leads to the production of anti-
nucleolar Abs, thus overcoming the genetic configuration
of autoimmunity [50].
Antigen spreading and its role in autoimmunity
Antigen spreading is significant in autoimmunity induced
in a mouse model by xenobiotics (procainamide, mercu-
ric chloride and gold (I)). Adoptive transfer of
CD4+CD25+ T cells from the xenobiotic-treated mice to
untreated mice inhibits the formation of antinuclear
autoantibodies. On the basis of these observations it was
suggested that the T cell reactivity induced by the xenobi-
otic treatment may spread from xenobiotic-induced,
nucleoprotein-related neoantigens to peptides of unal-
tered nucleoproteins [51].
Toll-like receptors and autoimmunity
The toll-like receptors (TLRs) are a germ-line-coded recep-
tor family that plays a pivotal role in innate immunity in
a wide spectrum of organisms from insects to mammals.
The innate immune response mechanism is either initi-
ated or activated by structures referred to as pathogen-
associated molecular patterns (PAMP), which are recog-
nized by corresponding pattern recognition receptors
(PRR). The best-characterized PAMPs are lipopolysaccha-
rides (LPS), peptidoglycans, mannans, bacterial DNA and
double-stranded bacterial RNA. Macrophages, B-cells and
dendritic cells (DC) express PRR. PRR are classified into
three specific types: secreted, endocytic and signaling.
Mannan binding lectin represents the secreted type, while
the macrophage mannose receptor belongs to the endo-
cytic class and the toll-like receptors (TLRs) are signaling
types [52].
TLRs are essential for detecting PAMPs, and this has been
identified as the first line of defense for pathogen recogni-
tion, for which a range of antimicrobial products and
numerous proinflammatory cytokines are generated by
the host. The Drosophila protein Toll that is required for
mounting an effective immune response to Aspergillus
fumigatus  has been identified as a lipopolysaccharide
(LPS) receptor. It plays a pivotal role in the primary recog-
nition of infectious pathogens by mammals [53].
TLRs are divided into five subfamilies on the basis of
amino acid sequence homology: TLR-1, 2, 6, 10; TLR-3;
TLR-4; TLR-5; and TLR-7, 8, 9. Structurally, the extracellu-
lar region of a TLR contains leucine-rich repeats flanked
by cysteine-rich motifs; a TOLL/IL-1 receptor (TIR)
homology domain in the cytoplasmic region is critical for
signaling. Given the sequence similarities between the TIR
domain and the cytoplasmic tails of IL-1 and IL-18 recep-
tors, it has been suggested that their signaling sequences
are similar (see box 12-1 and Figure 12-3 of [54].
Antigen (epitope-specific) recognition by B-cell receptors
(BCR) induces signals that cause B cell proliferation and
antibody production. Concurrent recognition by CD4 (T-
helper) cells generates specific cytokines that are essential
for antigen-specific antibody production by B-cells. It has
been conclusively demonstrated that loss of tolerance to a
given antigen by both B and T-cells is a primary cause of
autoimmune reactions [55]. B-cells are known to generate
anti-self IgG2a antibodies of low affinity. However, these
IgG2a can be recognized as immunogenic by B-cells and
as PAMP by TLRs, thus inducing autoantibodies to nuclear
antigens [56].
Concurrent activation of BCR and B-cell TLR-9 by such
IgG2a is due to recognition as non-self and results in the
formation of a self DNA (autoantigen)-IgG2a (autoanti-
body) immune complex. Binding of such a complex to
BCR triggers endocytosis, causing effective delivery of the
denatured chromatin fragments to endosome-associated
TLR-9. Activation of TLR-9 by exogenous or endogenous
CpG-DNA in MLR-Fas lpr/lpr mice induces the progression
of renal diseases [57]. It should be pointed out that
MyD88-dependent receptor activation is required for the
formation of autoantibody-autoantigen immune com-
plexes in adaptive immune responses [58].
Dendritic cells (DCs) engorged with a cardiac muscle-spe-
cific self (autoantigen) peptide caused CD4+-cell-medi-
ated autoimmune myocarditis, which progresses to
dilated cardiomyopathy and heart failure. It has been sug-
gested that this is a TLR-dependent process. Formation of
the self-peptide-loaded DCs may have been provoked by
various microbial epitopes acting via TLRs during chronic
infection [59]. One such factor may be uric acid. Studies
on DC maturation have shown that uric acid is a major
endogenous danger signal from injured cells. It induces
DC maturation in the presence of antigen and signifi-
cantly up-regulates the generation of responses originat-
ing from CD8+ T cells [60].
Thus, in the context of the hypothesis proposed here (see
below), it is possible that a host overloaded with one or
more antigenic determinants (epitopes) from one or more
infectious agents causes stress that in turn activates TLRs.Theoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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It is contended that by a yet uncharacterized mechanism,
this could lead to multi-drug resistance during the course
of treatment for these infections, and this could develop
into autoimmunity.
However, the free radical theory of autoimmunity pro-
posed here differs markedly from the "danger theory" of
immune activation proposed by Matzinger. Essentially,
this states that the host immune system does not differen-
tiate between self- and non-self- but mounts an effective
immune response only to danger signals originating from
necrotic or stressed cells [61].
In support of my contention, it has been proposed that
macrophages and DCs express TLR on their surfaces so
they can recognize PAMP and initiate appropriate signals
for inducing reactive oxygen and nitrogen intermediates.
Because this would also activate APCs by inducing pro-
inflammatory cytokines and up-regulate co-stimulatory
molecules for the activation of TLRs (see Figure 1, 2 and
Table 1 of [62]), it has been proposed that one possible
mechanism for the onset of autoimmunity is mediation of
the breakdown of peripheral tolerance by hyperactive
APCs, causing the activation of autoreactive cells [63].
I contend that autoimmunity resulting from COS is not an
all-or-none response but an evolutionary process that
engulfs the host immune system over a period of time.
Arguably, a danger signal could play a pivotal role in the
onset of autoimmune disorders, but this alone could
never account for the collapse of the host immune
response. For an effect of such magnitude, the host must
endure diverse stress signals that eventually lead to the
collapse of tolerance and trigger autoimmune reactions.
Although a particular TLR is responsible for ligand-
induced signaling, the TLR repertoire that confers ligand-
binding and signaling specificities results from het-
erodimerization and the participation of diverse non-TLR
adaptor molecules. Several adaptor molecules have been
identified and prominent among these are myeloid differ-
entiation factor 88 (MyD88), MyD88-adaptor-like/TIR-
associated protein (MAL/TIRAP), Toll-receptor-associated
activator of interferon (TRIF) and Toll-receptor-associated
molecule (TRAM). They transduce signals from all regions
homologous to the Toll/interleukin-1 receptor (IL-1R)
(TIR) domain. Such signals activate intracellular protein
kinases, which in turn activate transcription factors that
up-regulate inflammatory cytokine and fibrotic genes (see
Figure 1 in [64]). The function of a fifth adaptor, SARM
(sterile alpha and HEAT/Armadillo motif protein), has yet
to be defined [64]. The molecular basis of the TLR-associ-
ated signaling cascade has been discussed in detail else-
where [65].
TLR4/MD-2 and RP105/MD-1 signal the presence of LPS
in the host. RP105 is expressed on virtually all mature B-
lymphocytes. RP105/MD-1-mediated signaling induces
B-cell proliferation and the pathogenesis of systemic
lupus erythematosus (SLE) [66]. It has been suggested that
TLR9 activation triggers systemic autoimmunity and con-
tributes through adaptive and innate immune mecha-
nisms to the CpG-DNA-induced succession of lupus
nephritis [67].
Activation of naïve polyclonal B cell proliferation by TLR7
ligands such as resiquimod (R848) and loxoribine requires
the presence of plasmacytoid dendritic cells (PDCs),
whereas similar activation via the TLR9 ligand CpG is
independent of PDCs. Also, in the presence of type I inter-
feron (IFN), ligation of TLR7 triggers the multiplication of
polyclonal B cells and their subsequent differentiation
toward Ig-producing plasma cells. This process occurs
independently of T and B cell Ag [68].
TLR-9 induced lupus B cell activation has been shown to
modulate T-cell mediated inflammatory reactions
through IL-10. Furthermore, B-cell mediated lupus patho-
genesis can be mediated by B cells acting as APCs for auto-
antigens and autoantibody-producing effector cells. B-
cells are also sources of IL-10 [69].
Cross-presentation of peripheral self-Ags by DC can
induce deletion of auto-reactive CTL by cross-tolerance.
Activation of tolerogenic DC may cause autoimmunity by
stimulating autoreactive CTL. It was concluded that DC
activation by TLR ligands is insufficient to break periph-
eral cross-tolerance in the absence of specific CD4+ T
helper cells, so autoimmunity is promoted by stimulating
the early effector phase of autoreactive CTL only when
their precursor frequency is extremely high [70]
Cause and effect of COS in the onset of autoimmunity
Substantial improvement in the therapeutic regimen
increases the survival rate for cancer patients (62% of
adult and 77% of pediatric cancer patients survive beyond
5 years). It is therefore theoretically possible that the lin-
gering effects of radiation therapy and chemotherapeutic
drugs, or a combination of both, impart slow but finite
damage to non-cancerous tissues or cells. This condition
could therefore be described as a chronic disease, and the
late effects of radiation and chemotherapy on normal tis-
sues/cells remain a significant health risk [71].
Upon exposure to genotoxic agents, bioactive metabolites
are formed in vivo. These metabolites as well as the parent
compound damage subcellular components in a target
organ-specific manner. The extent of such damage
depends on the concentrations of metabolic intermedi-
ates or parent compounds and/or both. Exposure to toxicTheoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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chemicals can cause increased iron accumulation in the
spleen as a result of erythrocyte damage and free iron
release in the target organ. Accumulation of free iron has
been shown to cause the activation of phagocytic cells
(macrophages, neutrophils) and subsequent release of
reactive oxygen and nitrogen species in vivo [72-74].
The late effects of radiation and chemotherapeutic drugs
(and genotoxic compounds) on normal cells would lead
to activation of stress-response kinases (mitogen-activated
stress kinases – MAPK) and redox-sensitive transcription
factors, and up-regulate pro-inflammatory cytokines
[75,76]. The continued and ever-increasing presence of
chemotherapeutic drug metabolites, in combination with
substances released from the damaged tissues, are poten-
tial sources of as yet uncharacterized toxins. It is possible
that these compounds could cause an aberrant (chronic
inflammatory) response in vivo [77].
In such pathophysiological states, peripheral blood leu-
kocytes would probably be activated, leading to a sequen-
tial respiratory burst releasing ROS (H￿, ￿OH, O2 
￿- and
H2O2). Owing to its inherent instability and reactivity,
￿OH reacts with biological molecules in its vicinity within
10-9 s of its formation [78]. In addition to ROS in patho-
physiological states, iNOS, the inducible or calcium-inde-
pendent isoform of nitric oxide synthase, mediates the
formation of di-nitrogen trioxide (N2O3) and peroxyni-
trite (O = NOO-) (RNOS), causing nitrosative and oxida-
tive stress in vivo [79] and altering signaling cascades with
effects on the regulation of gene expression [80,81].
Protein nitration occurs as a result of oxidative stress.
Tyrosine residues are nitrated via the peroxynitrite-medi-
ated pathway, and haem-containing peroxidase catalyzed
reactions also occur. Nitrite (NO2 
-) is an end-product of
NO metabolism that can be oxidized by haem peroxi-
dases (e.g. horseradish peroxidase, lactoperoxidase and
myeloperoxidase) forming the reactive nitrogen species
NO2. Nitrite also reacts with tyrosine residues causing the
nitration of proteins. NO2 reacts with HOCl via a mye-
loperoxidase-catalyzed reaction between H2O2 and Cl-,
forming nitryl chloride (NO2Cl). NO2Cl also nitrates pro-
tein tyrosine residues.
S-Nitrosylated proteins are formed when cysteine thiol
groups react with nitric oxide (NO) in the presence of an
electron acceptor to form an S-NO bond. Nitrated pro-
teins are protected from reductive or transnitrosative deg-
radation by storage in membranous structures (e.g.
lipophilic protein folds, vesicles and interstitial spaces).
Caspases are typically sequestered in an S-nitrosylated
(inactive) form within the intermembrane spaces of mito-
chondria. Appropriate apoptotic stimuli (e.g. Fas-Fas lig-
and binding) release caspases into cytosol where they are
denitrosylated to initiate apoptosis. Hypoxia-inducible
factor I (HIF-1), stimulating proteins 1 and 3 (Sp1 and
Sp3), nuclear factor-κB (NF-κ B) and the prokaryotic tran-
scription factor OxyR are also affected by S- nitrosylation.
ROS/RNOS are transient, necessitating the use of reaction
products as biomarkers or indices of nitrosative and oxi-
dative stress in vivo. Oxidized products such as thiobarbi-
turic acid reaction products (TBARs), 4-hydroxynonenal
(4-HNE) and hexane are routinely considered markers of
lipid peroxidation in both animal models and patients
[82]. Furthermore, sustained nitrosative stress (increased
nitrotyrosine formation) has been observed post-irradia-
tion [83,84]. Increased lipid peroxidation has also been
reported in patients developing radiation pneumonitis
[85]. Hypoxia was identified in the rat lung 6 weeks after
a single dose of 28 Gy using the hypoxia marker pimoni-
dazole [86]. During hypoxia, increased ROS/RNOS pro-
duction and reduced antioxidant and antioxidant enzyme
production have been observed [87-89].
Sustained ROS/RNOS accumulation leads to COS in vivo.
Although the precise mechanisms involved are not known
at present, possibilities include reduced levels of the anti-
oxidant vitamins C and E [90,91], differential regulation
of the xanthine oxidoreductase system [92] and/or aber-
rant arachidonic acid metabolism [93].
Changes in protein conformation can cause aggregation
and accumulation in tissues in vivo. Metabolic activities
(possibly oxidative stress/nitrosative stress) can lead to
sustained changes in the levels of metal ions, chaperone
proteins and pH, leading to macromolecular crowding
and increasing the concentration of misfolded proteins in
the intracellular milieu. These changes have a significant
role in protein aggregation and consequent loss of func-
tional properties. It is equally possible that proteins with
altered conformation have toxic effects in the intracellular
milieu [94].
Despite the lack of direct evidence, it is feasible that pro-
teins with altered conformations may present sequences
similar to host self-antigenic determinants (epitopes) and
therefore play a role in neo-antigen formation, thus per-
turbing the host immune system and potentially contrib-
uting to the evolution of multidrug resistance-induced
autoimmunity.
As suggested earlier, pro-inflammatory cytokines (IL-2)
probably contribute to the loss of self-tolerance and pos-
sibly to the formation of neo-antigens. It is conceivable
that in malignant disorders, cells that are subjected to
stress (oxidative/nitrosative) become unresponsive to
ever-increasing doses of ionizing radiation or chemother-
apeutic drugs because of their altered state. Thus, theTheoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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patient would lose pre-existing antioxidant defense mech-
anisms, causing limited or no antioxidant defense. This
would pave the way for the loss of drug sensitivity and
multi-drug resistance, and also the generation of COS.
In summary, the aforementioned circumstances create a
state of imbalance between ROS/RNOS generation and
removal  in vivo, thereby causing oxidative/nitrosative
stress. My contention is that the intracellular environ-
ment, as outlined above, would be suitable for deregulat-
ing the immune mechanism(s) in the cancer patient.
Autoimmune mechanisms(s) would subsequently be trig-
gered, causing loss of self-tolerance and the development
of autoimmune disorders.
Activation of antioxidant mechanisms as cause of drug 
resistance: a critical appraisal
In essence, the multi-drug resistance (MDR) phenotype of
a given clinical tumor burden results from a combination
of factors including decreased uptake of cytotoxic anti-
neoplastic drugs and alterations in intracellular metabo-
lism impairing the capacity of such drugs to kill cells. As a
result, tumor cells do not adequately control the cell cycle,
and there is increased repair of DNA damage, decline in
apoptotic cell death and deregulated energy-dependent
efflux of cytotoxic drugs across the plasma membrane
[95].
Overexpression of Pgp, MDR-associated-protein 1
(MRP1/ABCC1) or ABCG2 has been positively correlated
with the evolution of MDR as well as cross-resistance to
structurally unrelated anti-neoplastic drugs in a clinical
tumor burden [96]. Of the several mechanisms suggested
to underlie the onset of MDR, ABCC1 (MRP1) and its
homologues ABCC2 (MRP2), ABCC3 (MRP3), ABCC6
(MRP6) and ABCC10 (MRP7) mediate the transport of
glutathione (GSH), glucuronate or sulfate conjugates of
organic anions [97]. Inhibitors of Pgp have been evalu-
ated as effective therapeutic measures for blocking the
efflux of chemotherapeutics used in clinical oncology.
Owing to the heterogeneity of a tumor burden (in partic-
ular colon, kidney or adrenocortex) endowed with both
Pgp- and non-Pgp-dependent mechanisms that cause
MDR, inhibitors of Pgp are of limited scope as adjuncts to
chemotherapy. Furthermore, the unexpectedly high mor-
tality rate has been attributed to intolerable tissue toxicity
that is partly due to the elevated plasma concentrations of
Pgp inhibitors [98]. An ideal chemotherapeutic trans-
porter antagonist with high transporter affinity and low
pharmacokinetic interaction with non-related drugs,
which would restore the efficiency of treatment in MDR
tumor burdens with no or minimum cytotoxicity, has yet
to be formulated [99]. On the basis of these observation it
is suggested that in a given clinical tumor burden, "intrin-
sic MDR" and "acquired MDR" might coexist, making
existing therapeutic interventions unable to prevent
relapse.
Oxidative stress and MDR
Chemosensitizers as an adjunctive components in combi-
nation therapy (chemotherapy) have a variable therapeu-
tic index. This approach is also known to generate
oxidative stress owing to the accumulation of ROS and
RNS in the intracellular milieu of a given MDR tumor. It
has been suggested that oxidative stress-induced apopto-
sis is a plausible cytotoxic effect of chemotherapeutics in
a MDR tumor burden [100-104].
Anti-oxidative (enzymatic and non-enzymatic) system and 
MDR
Antioxidants confer protection against oxidative stress by
quenching free radicals, chelating redox metals and inter-
acting with (and regenerating) other antioxidants within
the "antioxidant network". When optimal concentrations
are sustained in tissues and biofluids they can function in
both the aqueous and membrane domains. The most effi-
cient enzymatic antioxidants are superoxide dismutase,
catalase and glutathione peroxidase [105]. Non-enzy-
matic antioxidants include vitamins C and E, carotenoids,
thiols (glutathione, thioredoxin and lipoic acid), natural
flavonoids and melatonin [106]. Few antioxidants can
regenerate other antioxidants to restore the reduced intra-
cellular state via an "antioxidant network". The redox
cycles of vitamins E and C have this capacity, driven by the
redox potentials of the [Red/Ox] couple [107]. Antioxi-
dants attenuate ROS by binding to transition metal-con-
taining proteins, transferrin or ceruloplasmin, inhibiting
cellular reactions (Vitamin E) and detoxifying ROS and
RNS, (GSH, SODs, catalase) [108].
Role of thioredoxin (Trx)/thioredoxin reductase (TrxR) 
system in multi-drug resistance
Overexpression of thioredoxin reductase (TrxR) increases
growth rates and resistance to cytotoxic agents that induce
oxidative stress [109,110]. Detoxification of ROS and up-
regulation of antioxidant genes are plausible mechanisms
[111]. In tumor cells, the thioredoxin (Trx)/thioredoxin
reductase (TrxR) couple produces a reduced form of extra-
cellular Trx, which acts as a growth factor conferring pro-
tection from the NK-lysin, tumor necrosis factor-α and the
T-lymphocyte respiratory burst [112]. Effective inhibition
of the Trx/TrxR system increases the sensitivity of tumor
cells to chemotherapeutic compounds [113-115]. Thiore-
doxin and peroxiredoxin 1 are up-regulated in drug-resist-
ant breast cancer patients who are clinical non-responders
to docetaxel [116].Theoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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Role of the glutaredoxin reductase (GR)/glutaredoxin 
(GRX) system in drug resistance
Increased activity of antioxidants such as catalase, glutath-
ione peroxidase and DT-diaphorase, and increase in glu-
tathione level, are associated with the onset of resistance
in Chinese hamster cells chronically exposed to menadi-
one [117]. Increased expression the α,μ and π isoenzymes
of GST might confer a multidrug-resistant phenotype on
rat hepatic preneoplastic nodules [118]. Increases in
gamma-glutamyl transpeptidase (GGT) and gamma-
glutamylcysteine synthetase (GCS) have a role in the
acquired resistance to quinone toxicity in rat lung epithe-
lial cells [119]. Elevated GST activity might also contribute
to the conversion of breast tumors to a tamoxifen-resist-
ant phenotype [120].
Development of resistance to doxorubicin in human
erythroleukemia cells is correlated with an increase in
GSH and GST and related enzymes (glutathione peroxi-
dase, glutathione reductase) [121]. Genomic amplifica-
tion resulting in an increase in GST-π expression has been
observed in head and neck squamous cell carcinoma cell
lines models and also in clinical tumor burdens resistant
to cisplatin. Clinical reports confirm mortality in patients
with GST-π amplification in the entire tumor burden sub-
sequent to chemotherapy [122]. GST-π been shown to
attenuate the formation of the 7-(2-oxo-hepyl)-substi-
tuted 1, N(2)-etheno-2'-deoxyguanosine adduct with 2'-
deoxyguanosine in human colonic cancer cells that are
resistant to anticancer drugs [123].
siRNA-mediated down-regulation of GRX-2 in HeLa cells
induces an increased sensitivity to doxorubicin and phe-
nylarsine oxide. In normal HeLa cells, exposure to non-
lethal oxidative stress causes an increase in endogenous
GRX-2. This has been implicated in protection against
toxic compounds that induce oxidative stress [124].
CAL1 human melanoma cells overexpress GST-μ1 after
exposure to anticancer drugs (vincristine, chlorambucil).
A concurrent increase in both GST-μ1 and MRP-1 might
have a role in protection against vicristine-mediated cyto-
toxicity [125]. Also, it has been suggested that GRX-2 is
pivotal in the glutathionylation and deglutathionylation
of proteins via multiple signaling pathways in a wide
range of GSH/GSSG ratios associated with different cellu-
lar redox states [126]. The transcription factor Nrf2 medi-
ates the up-regulation of γ-GCS and GSH synthesis, and
induces resistance to Imatinib (BCR/ABL tyrosine kinase
inhibitor) in chronic myelogenous leukemia [127].
Activation of glutathione peroxidase and glutathione
reductase was observed in the onset of radio resistance
and cross-resistance to chemotherapeutic agents in gliob-
lastoma [128]. Increased binding of AP-1 (activator pro-
tein-1) activity, observed in an electrophoretic mobility
shift assay, was suggested as the molecular mechanism by
which GST is overexpressed, in turn conferring resistance
to doxorubicin in leukemia [129].
Overexpression of GRX-2 in HeLa cells confers a signifi-
cant antiapoptotic and pro-survival effect upon exposure
to doxorubicin and phenylarsine oxide, possibly via inhi-
bition of cytochrome c release [130]. Pancreatic cancer
cells exposed to triterpenoid 2-cyano-3,12-dioxooleyl-
1,9-diene-28-imidazolide (CDDO-Im) caused the deple-
tion of mitochondrial glutathione, leading to apoptosis
[131].
A suggested downstream target of redox-sensitive signal-
ing is ribonucleotide reductase, which is likely to play a
significant role in the antioxidant-mediated protection of
tumor cells [132]. Glutathione peroxidase 1 and GST-π1
are up-regulated in breast cancer patients who are clinical
non-responders to docetaxel but show drug resistance
[133].
Role of redox-sensitive signaling proteins and MDR
Metallothioneins (MTs)
MTs are zinc-binding protein thiols with antioxidant
attributes that increase in tumor cells. This observation
suggests that overexpression of MTs is significant in the
acquisition of drug resistance in human tumor cells [134].
Superoxide dismutase (SOD)
A significant increase in SOD may be involved in the con-
version of breast tumors to a tamoxifen-resistant pheno-
type [120]. Mn-SOD-dependent activation of the zinc-
dependent matrix metalloproteinase family (MMP-1,-2)
has been positively correlated with an increased incidence
of metastasis in gastrointestinal tumors [135]. Also,
increased Mn-SOD activity confers resistance to doxoru-
bicin in human erythroleukemia cells [121]. It has been
suggested that up-regulation of SOD is significant in the
onset of radioresistance and cross-resistance to chemo-
therapeutic agents in glioblastoma [136].
Vitamin C
The role of Vitamin C in decreasing the incidence of stom-
ach, lung and colorectal cancer may be attributable to the
inhibition of N-nitroso compound generation [137].
Flavonoids
A regular intake of flavonoids such as polyphenols and
quercetin is linked to lower incidences of gastrointestinal
and also lung and breast cancer [138].
Selenium
Se (200μg/day) seems to reduce the incidences of lung,
colon and prostate cancer [139,140]. Increased levels ofTheoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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antioxidant enzymes (SOD, catalase, glutathione peroxi-
dase) and non-enzymatic antioxidants (GSH, vitamin C,
thioredoxin) are significant in several clinical tumor bur-
dens [141].
Collectively, antioxidants confer a reducing intracellular
environment enabling tumor burdens with MDR to evade
apoptosis and acquire growth advantage with increased
cell survival signals [142]. For these reasons, the "redox
buffering" capacity of a given tumor burden is a potential
therapeutic target for effective cancer-preventive and ther-
apeutic drug design [143].
Summary
Oxidative stress induces conformational changes in intra-
cellular proteins containing cysteine residues, triggering
ionization of the sulfhydryl moiety (-CH2SH to -CH2S-).
Pro-survival genes are up-regulated in a reduced intracel-
lular state. It is suggested that increased expression of pro-
survival genes enables tumor cells to evade chemothera-
peutically-induced cytotoxicity, conferring an adaptive
growth advantage that aggravates the tendency of tumor
cells with MDR to repopulate the tumor burden. This
leads to relapse and the subsequent development of
autoimmunity via several chronic redox state-dependent
reaction cascades.
Hypothesis
The following proposal (illustrated in Figure 1) accounts
for the role of COS as an essential element in the evolu-
tion of drug resistance-mediated induction of autoimmu-
nity. The hypothetical scheme is based on the premises
outlined above, and defines a possible sequence of events
beginning from radiation therapy/chemotherapy and
leading to the evolution of autoimmune disorders.
As shown in Figure 1, the toxicity consequent on radiation
therapy/chemotherapy is due to the metabolic derivatives
Figure 1Theoretical Biology and Medical Modelling 2006, 3:22 http://www.tbiomed.com/content/3/1/22
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and/or ionic overload (imbalance). These, in turn, induce
the activation of phagocytes and the associated respiratory
burst causing the release of ROS and RNS. Lymphocytes (T
and B cells) that are subjected to oxidative stress are more
sensitive to such stress. Lymphocytes exposed to H2O2
exhibit extensive genomic damage (DNA strand breaks).
Oxidative/nitrosative stress-induced alteration in the host
lymphocyte genome is likely to engender aberrant cellular
pathways that could lead to rapid cell lysis (necrosis) or
programmed cell death (apoptosis). Owing to the over-
whelming ROS/RNS, the antioxidant reserve may be
depleted or inactivated by one or more mechanism(s).
Such an intracellular environment would be conducive to
lipid peroxidation and accumulation of oxidized lipid-
derived aldehydes.
Lipid peroxidation-derived aldehydes are a potential
source of protein modification (oxidation resulting in car-
bonylation and nitrosation). This phase could be classed
as a state of acute oxidative stress. It is recognized that
acute oxidative stress causes genomic and/or mitochon-
drial DNA damage. As a result, it is conceivable that pro-
apoptotic gene expression would be up-regulated. Should
this become overwhelming, the tumor cells are pro-
grammed to die by apoptosis (First Selection). These
processes would be exacerbated if the DNA repair mecha-
nisms in vivo failed or were defective.
It is possible that during acute oxidative stress, anti-apop-
totic proteins/drug resistance genes may be overexpressed
in a select but limited number of tumor cells. It is also pos-
sible that those cells may have endured minimal or no
loss of anti-oxidant defense. The select cell population
would therefore survive and eventually cope with the
ensuing COS. Such a pathophysiological state would
obviously lead to inflammation, engendered by inflam-
matory cytokines and tumorigenic chemokines, which in
turn prompt deregulation of the immune defense mecha-
nisms.
Should there be a loss of antioxidant defense or failure of
adaptive mechanisms, or both, vulnerable tumor cells
would be programmed to undergo apoptosis (Second
Selection). Essentially, COS acts as a regulator for select-
ing the most tolerant tumor cell population, which is
adapted to survive radiation/genotoxic insults. But there
are no adequate signaling mechanism(s) in these aberrant
cells, impairing their ability to sustain homeostasis.
The COS-induced impairment of the intracellular meta-
bolic machinery again causes sustained genomic DNA
damage and potentially depletes the antioxidant reserve.
This may occur either concurrently or sequentially and
lead to the multi-drug resistant genotype, as well as facili-
tating the formation of neo-antigens. It has previously
been hypothesized that, owing to the loss of tolerance to
autoantigens and sustained accumulation of neo-anti-
gen(s), an autoimmune response would be likely to
evolve [144,145].
A factor that has frequently been overlooked in the in vivo
context is that cells undergoing apoptosis or necrosis
release considerable amounts of proteolytic enzymes and
other mediators. It is conceivable that these factors would
be detremental to normal as well as multi-drug-resistant
tumor cells. They would cause havoc in intracellular sign-
aling, contributing to the alteration in gene expression. It
is also possible that these factors would lead to cell death
via either apoptosis or necrosis (Second Selection).
Those normal cells that acquire tumor-resistant genotypes
are successful in passing through all the selection proc-
esses and would eventually emerge as multidrug-resistant
cells. Under these circumstances, accumulation of neo-
antigens or other inflammatory cytokines would also dec-
imate the host immune defenses. These events lead to an
intracellular milieu conducive to a lethal breakdown in
host self-tolerance. This, in turn, causes a surge in immune
disorders, leading to the sequence of events that result in
autoimmunity.
Should this effect prevail, it would be a potential cause of
death in a cancer patient. Therefore, an effective means of
treating the lymphoproliferative disorders that result from
failure of therapeutic measures is to delineate the precise
molecular mechanisms leading to COS and the conse-
quent genomic DNA damage and expression and regula-
tion of repair proteins. Only a combination of therapeutic
measures can attenuate or disengage the pathophysiolog-
ical consequences of these deleterious COS-induced
effects on tumor cells.
In summary, these COS-induced effects would directly (i)
alter signal transduction and (ii) induce epigenetic mech-
anisms (hypo/hyper-methylation; hypo/hyper-acetyla-
tion of the elements that regulate anti-apoptotic or pro-
apoptotic genes) [146-151]. In the context of COS as a
regulatory element in the evolution of autoimmunity,
alterations in cytokines (IL-2 expression) would exert the
most significant impact next to the neoantigens. Thera-
peutic measures directed at modulating such epigenetic
mechanism(s) in a development stage-specific manner
(lymphoproliferative disorder) would potentially attenu-
ate the impact of drugs and the subsequent evolution of
autoimmune disorders.
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